| Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty‐two–week randomized, double‐blind, placebo‐controlled study W Stohl, A Schwarting, M Okada, M Scheinberg, A Doria, AE Hammer, ... Arthritis & Rheumatology 69 (5), 1016-1027, 2017 | 351 | 2017 |
| A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea F Zhang, SC Bae, D Bass, M Chu, S Egginton, D Gordon, DA Roth, ... Annals of the rheumatic diseases 77 (3), 355-363, 2018 | 263 | 2018 |
| Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review E Sarnes, L Crofford, M Watson, G Dennis, H Kan, D Bass Clinical therapeutics 33 (10), 1413-1432, 2011 | 254 | 2011 |
| Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial HI Brunner, C Abud-Mendoza, DO Viola, IC Penades, D Levy, J Anton, ... Annals of the rheumatic diseases 79 (10), 1340-1348, 2020 | 129 | 2020 |
| A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in … BH Rovin, R Furie, YKO Teng, G Contreras, A Malvar, X Yu, B Ji, Y Green, ... Kidney international 101 (2), 403-413, 2022 | 123 | 2022 |
| Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression A Mahajan, J Amelio, K Gairy, G Kaur, RA Levy, D Roth, D Bass Lupus 29 (9), 1011-1020, 2020 | 119 | 2020 |
| Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan C Garris, P Jhingran, D Bass, NM Engel-Nitz, A Riedel, G Dennis Journal of medical economics 16 (5), 667-677, 2013 | 109 | 2013 |
| Phase III/IV, randomized, fifty‐two–week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus E Ginzler, LS Guedes Barbosa, D D'Cruz, R Furie, ... Arthritis & Rheumatology 74 (1), 112-123, 2022 | 62 | 2022 |
| Efficacy and safety of subcutaneous belimumab in anti–double‐stranded DNA–positive, hypocomplementemic patients with systemic lupus erythematosus A Doria, W Stohl, A Schwarting, M Okada, M Scheinberg, ... Arthritis & Rheumatology 70 (8), 1256-1264, 2018 | 62 | 2018 |
| A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus W Chatham, A Chadha, J Fettiplace, C Kleoudis, D Bass, D Roth, ... Lupus 26 (14), 1483-1490, 2017 | 46 | 2017 |
| Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre … SZ Sheikh, MA Scheinberg, JCC Wei, D Tegzova, W Stohl, RA de Toledo, ... The Lancet Rheumatology 3 (2), e122-e130, 2021 | 33 | 2021 |
| 200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study D D’Cruz, K Maksimowicz-McKinnon, J Oates, MB Santiago, D Bass, ... Lupus Science & Medicine 6 (Suppl 1), 2019 | 29 | 2019 |
| A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus A Doria, D Bass, A Schwarting, A Hammer, D Gordon, M Scheinberg, ... Lupus 27 (9), 1489-1498, 2018 | 29 | 2018 |
| The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis C Wilkinson, RB Henderson, AR Jones-Leone, SM Flint, M Lennon, ... Arthritis Research & Therapy 22, 1-11, 2020 | 28 | 2020 |
| Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea Y Tanaka, SC Bae, D Bass, P Curtis, M Chu, K DeRose, B Ji, R Kurrasch, ... RMD open 7 (2), e001629, 2021 | 22 | 2021 |
| Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a phase 3 randomized placebo-controlled trial Y Tanaka, D Bass, M Chu, S Egginton, B Ji, H Struemper, D Roth Modern Rheumatology 29 (3), 452-460, 2019 | 21 | 2019 |
| A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR) J Patel, D Bass, A Beishuizen, XB Ruiz, H Boughanmi, A Cahn, ... European Respiratory Journal 61 (2), 2023 | 18 | 2023 |
| A randomized, double-blind, placebo-controlled, 52-week study of the efficacy and safety of belimumab administered subcutaneously plus standard care to patients with systemic … W Stohl, A Schwarting, M Okada, M Scheinberg, A Doria, A Hammer, ... ARTHRITIS & RHEUMATOLOGY 67, 2015 | 16 | 2015 |
| Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison HI Brunner, C Abud-Mendoza, M Mori, CA Pilkington, R Syed, S Takei, ... Rmd Open 7 (3), e001747, 2021 | 15 | 2021 |
| Impact of belimumab on organ damage in systemic lupus erythematosus MB Urowitz, C Aranow, Y Asukai, DL Bass, IN Bruce, D Chauhan, ... Arthritis Care & Research 74 (11), 1822-1828, 2022 | 14 | 2022 |
